Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 218 % -51.8%
Debt-to-equity 47.1 % +27.7%
Return On Equity -46.3 %
Return On Assets -79 % -107%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.2M shares +23%
Common Stock, Shares, Outstanding 22.2M shares +23.6%
Entity Public Float 106M USD +2.91%
Common Stock, Value, Issued 22K USD +22.2%
Weighted Average Number of Shares Outstanding, Basic 20.2M shares +12.1%
Weighted Average Number of Shares Outstanding, Diluted 20.2M shares +12.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 131K USD -47.4%
Research and Development Expense 31.8M USD +80%
General and Administrative Expense 9.77M USD +2.27%
Operating Income (Loss) -41.5M USD -53.9%
Nonoperating Income (Expense) 193K USD
Net Income (Loss) Attributable to Parent -41.3M USD -50.4%
Earnings Per Share, Basic -2.18 USD/shares -43.4%
Earnings Per Share, Diluted -2.18 USD/shares -43.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.6M USD -19.8%
Accounts Receivable, after Allowance for Credit Loss, Current 1.11M USD
Assets, Current 35.9M USD -21.4%
Operating Lease, Right-of-Use Asset 335K USD -24.6%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 82K USD -36.4%
Assets 52.8M USD -15.8%
Liabilities, Current 13.8M USD -3.71%
Operating Lease, Liability, Noncurrent 284K USD -34%
Liabilities 14.1M USD -21.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.04M USD -41%
Retained Earnings (Accumulated Deficit) -154M USD -36.6%
Stockholders' Equity Attributable to Parent 38.7M USD -12%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 52.8M USD -15.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.48M USD -555%
Net Cash Provided by (Used in) Financing Activities -2.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 22.2M shares +23.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.85M USD -756%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.6M USD -19.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 19.6M USD +42.8%
Deferred Tax Assets, Gross 19.6M USD +43.1%
Operating Lease, Liability 419K USD -21.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.6M USD -53.8%
Lessee, Operating Lease, Liability, to be Paid 535K USD
Operating Lease, Liability, Current 135K USD +27.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 198K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 192K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 83K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.85M USD +25.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Additional Paid in Capital 194M USD +23.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 545K USD
Share-based Payment Arrangement, Expense 1.72M USD -9%
Interest Expense 1.22M USD -74.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%